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Transmembrane domainThe transmembrane (TM) domains of receptor tyrosine kinases (RTKs) are believed to be important players
in RTK signal transduction. However, the degree of speciﬁcity and promiscuity of RTK TM domain lateral
interactions in mammalian membranes has not been assessed in detail in the literature. A technique to probe
the occurrence of interactions between TM domains and their biological signiﬁcance is to evaluate the
propensity for formation of heterodimers of a full-length RTK and its TM domain. Here we examine if the
inhibition of two RTK pathogenic mutants, Neu/V664E and FGFR3/A391E, can be achieved by the TM
domains of Neu, Neu/V664E, FGFR3 and FGFR3/A391E. We show that the TM domain of Neu/V664E
speciﬁcally inhibits the phosphorylation of full-length Neu/V664E, while the wild-type Neu TM domain does
not. In addition, Neu/V664E TM domain does not affect the phosphorylation levels of full-length FGFR3/
A391E. The results suggest that TM domain peptides could be exploited in the future for the development of
speciﬁc inhibitors of mutant RTKs.l rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
RTKs are single-pass transmembrane (TM) proteins which are
composed of four distinct domains: an extracellular (ligand-binding)
domain, a single TM domain, a juxtamembrane, and a catalytic domain.
They transduce biochemical signals via lateral dimerization in the
plasma membrane. The dimerization process is controlled by the
presence of ligands [1], which stabilize the RTK dimers upon binding to
their extracellular domains. RTK dimerization is tightly linked to RTK
activity, because the contact between the two catalytic domains in
the dimer stimulates catalytic activity, and triggers signaling cascades
[2–4].
The role of the TM domains in the dimerization process has been
highly controversial. While in some studies TM domains have had
negligible effects on signaling, suggesting that the TM domains are
passive anchors [5,6], in other cases changes in the sequences of the
TM domains have affected signaling [7,8]. Studies of the isolated TM
domains in lipid bilayers or bacterial membranes have showed that
RTK domains can dimerize by themselves [9–13], suggesting that the
TM domains contribute to the energetics of RTK dimerization. Most of
these studies have utilized genetic two-hybrid assays (ToxR, TOXCAT,
GALLEX) that measure the interaction of membrane spanning helices
linking a periplasmic maltose binding protein (MBP) with a cytosolic
DNA-binding domain that is activated upon dimerization [9,14–17]. Inaddition, FRET-based dimerization measurements [18–20] of the
isolated TM domains of ErbB1, FGFR3 and EphA1 [10,11,21] have
demonstrated that these TM domains can form homodimers in lipid
bilayers [10,11,21]. Another very strong argument for the important
roles of the TM domains in signaling is the ﬁnding that pathogenic
mutations in TM domains promote ligand-independent dimerization
and cause disease [22–25]. Inmodel systems such pathogenicmutants
can exhibit higher dimerization propensities than the wild-type RTK
TM domains [12,25,26].
While dimerization between isolated TMdomains has been shown to
occur in model systems, and to be enhanced due to pathogenic single
amino acid mutations, direct demonstrations of dimerization of isolated
RTKTMdomains inmammalianmembranes are lacking.Hereweemploy
chemical cross-linking and verify that dimerization between isolatedRTK
TM domains can occur inmammalianmembranes. Another technique to
probe the occurrence of interactions between TM domains and their
biological signiﬁcance is to evaluate the propensity for formation of
heterodimers of a full-length RTK and its TM domain [27–29]. The
presence of such heterodimers, which are inactive, is expected to
decrease RTK phosphorylation if RTK TM domain interactions are
signiﬁcant for biological function. This approach could also be developed
into a targeted treatment strategy [29]. However, this strategy will be
viable only if the interactions between RTK TM domains are highly
speciﬁc (i.e. homodimerization strengths greatly exceed heterodimeriza-
tion strengths). The question of speciﬁcity, however, has not been
investigated much in the literature. One paper reports that the
phosphorylation level of EGFR can only be inhibited by the TM domain
of EGFR, but not the TMdomains of an EGFRmutant, ErbB2 or the insulin
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only be targeted by its own TM domain [30]. Yet, others argue that RTK
interactions are, in fact, quite promiscuous [31]. For instance, many RTK
TM domains have GxxxG-like interaction motifs and capabilities for
hydrogen bonding with backbone donors and acceptors that in principle
could drive promiscuous TM domain heterodimerization [9,25,32].
Of the different 59 RTKs found in humans, two RTK sub-families
have been studied most extensively: ErbB (ErbB1, ErbB2, ErbB3, and
ErbB4) and FGFR (FGFR1, FGFR2, FGFR3, and FGFR4). ErbBs play a role
in cancer progression and metastasis [33–35]. On the other hand,
FGFRs have been linked to skeletal dysplasias, craniosynostoses, and
cancer [36–39]. Many of these abnormalities have been linked to
mutations in the TM domains of these receptors. One suchmutation is
the V664E mutation in rat Neu/ErbB2, shown to be oncogenic [40,41].
In humans, a different mutation to glutamic acid, A391E in FGFR3, has
been identiﬁed as a germ-line mutation in Crouzon syndrome with
acanthosis nigricans [24] and as a somatic mutation in bladder cancer
[38]. Both mutations are believed to stabilize the mutant RTK dimers
via hydrogen bonding between the two TM domains [42]. Since both
Neu and FGFR3 TM domains have GxxxG-motifs and abundant
moieties with hydrogen bonding capabilities (every peptide bond in
a TM helix can serve as hydrogen bond donor or acceptor), a question
arises as to whether promiscuous hetero-interactions may occur
between these two TM domains in the plasma membrane, or whether
alternatively these TM domains engage only in speciﬁc homodimer-
ization interactions in the plasma membrane. To start addressing
these important questions of speciﬁcity and promiscuity in cellular
membranes, here we examine if the inhibition of the two pathogenic
mutants, Neu/V664E and FGFR3/A391E, can be achieved by the TM
domains of Neu, Neu/V664E, FGFR3 and FGFR3/A391E.
While some of the experiments involving FGFR3 TM domains are
inconclusive due to the impaired trafﬁcking of these TM domains to
the plasma membrane, here we show that the TM domain of Neu/
V664E has a modest, yet speciﬁc inhibitory effect on the phosphor-
ylation of full-length Neu/V664E. In addition, Neu/V664E TM domain
does not affect the phosphorylation level of full-length FGFR3/A391E,
indicating that the interactions between mutant RTKs and their TM
domains are speciﬁc. Thus, the mutant TM domain peptides could be
exploited in the development of speciﬁc inhibitors of mutant RTKs.
2. Materials and methods
2.1. Cell culture
B104-1-1 cells, a NIH 3T3 transfectant that stably expresses the Neu/
V664Emutant, were cultured in DMEM (Invitrogen, CA) supplemented
with 10% Bovine Calf Serum (Hyclone Laboratories, UT). Human
Embryonic Kidney (HEK) 293 cells were cultured in DMEM supple-
mentedwith 10% Fetal Bovine Serum (FBS). Cells weremaintained in an
incubator with 5% CO2 at 37 °C.
2.2. Construction of plasmids encoding RTK TM domains
Genes encoding the TM sequences of ﬁbroblast growth factor
receptor 3 (FGFR3), FGFR3/A391E, Neu and Neu/V664E were inserted
in a pcDNA 3.1(+) vector (Invitrogen, CA) by ligation of the
transmembrane PCR products using the HindIII and XbaI restriction
sites. The ﬁnal sequences contained the FGFR3 signal peptide, a VSV-
G-tag and the sequences of the TM domains.
2.3. Transfection and immunostaining
Transfection of the plasmids into B104-1-1 cells was performed
using Lipofectamine™ 2000 transfection reagent (Invitrogen, CA)
according to themanufacturer's protocol. Transfection of the plasmids
into HEK 293 cells was performed using Fugene HD (Roche AppliedScience, IN). Cells were cultured in the incubator for 24 h after
transfection. After being ﬁxed by 3% paraformaldehyde (PFA), cells
were blocked using bovine serum albumin (BSA) for 1 h. Cells were
then incubated with anti-VSV-G antibodies (Sigma-Aldrich, MO)
overnight at 4 °C. The secondary antibody used was Alexa Fluor 647
goat anti-rabbit IgG (H+L) (Invitrogen, CA).2.4. Western blotting
After culturing the cells in the incubator for 24 h following
transfection, cells were lysed with lysis buffer (25 mM Tris–HCl, 0.5%
TritonX-100, 20 mM NaCl, 2 mM EDTA, 2 mM NaVO4 and protease
inhibitor) (Roche Applied Science, IN). After spinning at 15,000 g for
15 min at 4 °C, the supernatant was collected and the pellet was
discarded. Protein concentration was determined using the BCA™ assay
kit (Pierce, IL). The lysate was loaded into 3–8% NuPAGE® Novex® Tris-
Acetate mini gels (Invitrogen, CA). Proteins were separated by electro-
phoresis, and transferredonto anitrocellulosemembrane. Themembrane
was blocked with milk for one hour at room temperature, and then
stained with one of the following antibodies: anti-C-Neu (Santa Cruz
Technology, CA), anti-N-FGFR3 (Santa Cruz Technology, CA), anti-p-
ErbB2 (Cell Signaling Technology, MA), anti-p-FGFR3 (Cell Signaling
Technology, MA) and anti-VSV-G antibodies (Sigma-Aldrich, MO). The
secondary antibodies were anti-mouse or anti-rabbit HRP conjugated
antibodies (Promega, WI). ECL™ detection reagent (GE Healthcare Life
Sciences, UK) was used to reveal the bands on the ﬁlms. The bands were
quantiﬁed using ImageQuant TL (GE Healthcare Life Sciences, UK).2.5. Cross-linking of TM domains using membrane permeable linkers
Twenty-four hours after transfection, cells were incubated in 2 mM
Ethylene Glycol Bis (sulfosuccinimidyl) substrate (EGS, Pierce, IL) for
one hour at room temperature, and then quenched in 20 mM Tris–HCl
for 15 min. After two rinses with ice-cold PBS, cells were lysed and
subjected to Western blotting.2.6. Quantiﬁcation of Western blots
The Western blot ﬁlms were scanned and processed with Image-
Quant TL. At least three sets of independent experimentswereperformed
in order to determine the averages and the standard deviations. The
Student t-test was performed to analyze statistical signiﬁcance.2.7. Creation of stable HEK 293 cell lines expressing FGFR3/A391E
HEK 293 cells were transfected with plasmids encoding FGFR3/
A391E. Twenty-four hours after transfection, culture medium was
replaced by medium supplemented with 0.6 μg/ml Geneticin® (G418
from Invitrogen, CA). Two or three days later, the cells which grew to
about 90% conﬂuencywere passed and seededwith high dilution ratio
into a 150 mm cell culture dish. The medium with antibiotics was
replaced every two to three days until colonies of cells appeared
around two weeks after the initial seeding.2.8. Statistical analysis
Data were analyzed for signiﬁcance using the Student t-test in
Microsoft Excel to compare the measurements to a null hypothesis.
The p-value cutoff for signiﬁcance was determined using the
Bonferroni correction for multiple comparisons. ANOVA was used to
compare results for the four different TM domains.
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VSV-G tag TM sequenceSignal peptide
Fig. 1. Plasmids encoding Neu and FGFR3 TM domains. (A) The amino acid sequences of FGFR3, FGFR3/A391E, Neu and Neu/V664E TM domains. The amino acids in the hydrophobic
hydrocarbon core-embedded domain are underlined. The mutant amino acids (E) are shown in italic. (B) Structure of the constructed genes, containing the FGFR3 signal peptide at
the N-terminus, a VSV-G tag for probing expression, and the TM domains.
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3.1. Expression of Neu and FGFR3 transmembrane domains
PCR products encoding the transmembrane domains (with amino
acid sequences shown in Fig. 1A) were cloned into the pcDNA 3.1+
vector. All constructed TM plasmids contained a Vesicular Stomatitis
Virus glycoprotein (VSV-G) tag (YTDIEMNRLGK) at the N-terminus
(Fig. 1B). The VSV-G tag comprises amino acids 501–511 of the
Vesicular Stomatitis Virus glycoprotein and has been widely used as a
tag in expression vectors [43,44]. The engineered VSV-G tag allowed
the detection of the TM domains on the cell surface using an anti-VSV-Fig. 2. Immunoﬂuorescent staining of the TMdomains inHEK 293 cells. (A) FGFR3 TMdomain.
were stained with anti-VSV-G antibodies, followed by Alexa Fluor 647 goat anti-rabbit IgG (H+
Neu/V664E TMexpress at the cell surfacewith higher efﬁciency, only a small fraction of cells exp
with results shown in Fig. 3 suggest that the FGFR3 TM domains are not trafﬁcked efﬁciently tG antibody. The construct also contained the signal peptide of FGFR3
at the N-terminus, to direct the proteins to the plasma membrane.
In order to conﬁrm the expression of the transmembrane domains in
the cells and their localizationon the cellmembrane,HEK293andB104-
1-1 cells were transfected with the four plasmids encoding the TM
domains of FGFR3, FGFR3/A391E, Neu and Neu/V664E. Twenty-four
hours after transfection, the membrane localization of the expressed
proteins was probed using anti-VSV-G antibodies followed by ﬂuores-
cently-tagged secondary antibodies. The confocal microscope images in
Fig. 2 show the staining patterns of the expressed TM domains in HEK
293 cells (A–D). All four TM domains could be detected on the cell
surface. However, the cells transfected with the plasmids encoding(B) FGFR3/A391E TMdomain. (C) Neu TMdomain. (D)Neu/V664E TMdomain. Intact cells
L). Images were acquired with a Nikon confocal laser scanning microscope. Neu TM and
ress FGFR3 and FGFR3/A391E TMdomains in their plasmamembrane. These results, along
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Fig. 4.Western blot analysis of the TM domains after chemical cross-linking. B104-1-1
cells were transfected with plasmids encoding the TM domains of FGFR3 (lane 1),
FGFR3/A391E (lane 2), Neu (lane 3) and Neu/V664E (lane 4). Twenty-four hours after
transfection, cells were subjected to cross-linking, followed by lysis and Western
blotting. Dimeric bands were observed for all constructs. The cross-linker used was
ethylene glycol succinimidyl succinate (EGS), a membrane permeable linker that cross-
links proteins within all cellular membranes [42].
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percentage of stained cells compared with those cells transfected with
the Neu/WT and Neu/V664E TMdomain plasmids. Different versions of
FGFR3 TM domains were designed (not shown here) containing
extracellular and cytoplasmic sequences of different lengths, and they
exhibited similar low propensities for membrane localization, signiﬁ-
cantly lower than the propensities of Neu and Neu/V664E TM domains.
These results for HEK 293 cellswere similar to results for B104-1-1 cells,
with Neu and Neu/V664E TM domains more abundant on the cell
surface than FGFR3 and FGFR3/A391E TM domain (not shown).
The poor expression of FGFR3 TM domains on the cell surface was
unexpected because all four plasmidswere very similar, with identical
signal peptide sequences and TM domains of very similar hydropho-
bicity. Thus, a question arised if the lower FGFR3 TM domain
concentration on the cell surface was due to overall lower expression
in cells or due to impeded trafﬁcking of FGFR3 TM domains to the cell
surface. To answer this question, we assessed the expression of the
four TM domains in B104-1-1 and HEK 293 cells using Western
blotting. In Fig. 3, we see bands at about 6 kDa that are reactive to the
VSV-G tag. The FGFR3/A391E and Neu/V664E TM domain bands
appeared at lower apparent molecular weights than the wild-type
bands, probably due to the negative charge of the glutamic acid in
FGFR3/A391E and Neu/V664E. We see that while the expression of
FGFR3/A391E TM domain was lower than that of FGFR3/WT domain,
there was no signiﬁcant difference in the expression levels of FGFR3/
A391E, Neu/WT and Neu/V664E TM domains. Thus, the observed
difference in immunostaining patterns in Fig. 2 was not due to
differences in overall expression. Instead, it appears that the FGFR3
TM domains were not being trafﬁcked efﬁciently to the cell surface.
3.2. Dimerization of transmembrane domains in cellular membranes
The overall goal of this study was to assess the potential inhibitory
effects of the TM domains on the activation of Neu/V664E and FGFR3/
A391E. While these peptides dimerize in model systems [9,12,13,17],
their dimerization in mammalian membranes has not been demon-
strated directly. Therefore, we ﬁrst sought to prove that the
transmembrane domains have a propensity to dimerize in cellular
membranes using chemical cross-linking, a technique that is widely
used to assess dimerization propensities [22,45,46]. We used a
membrane permeable chemical cross-linker, ethylene glycol succini-
midyl succinate (EGS), to cross-link the TM domains within all theA
B





Fig. 3. Western blot analysis of the expression of the TM domains in B104-1 cells (A) and
HEK 293 cells (B). Cells were transfectedwith the same amount (1 μg of plasmid per well)
of pcDNA3.1+ plasmids encoding the TM domain of FGFR3 (lane 1), FGFR3/A391E (lane
2), Neu (lane 3) and Neu /V664E (lane 4). Cells were lysed 24 h after transfection. The
proteinswere separated on a SDS-PAGE gel and detectedwith anti-VSV-G antibodies. The
expression of the four TM constructs is comparable.cellular membranes, not only the plasmamembrane [42]. Fig. 4 shows
the Western blot result from such a cross-linking experiment. Two
different bands were observed on the gel. One band appeared at about
6 kDa, corresponding to the monomeric TM domains, and another
appeared at approximately 12 kDa, corresponding to the dimeric TM
domains. These results suggest that the four TM domains can dimerize
in cells. We quantiﬁed the intensities of the monomeric and dimeric
bands, calculating the ratios R=(dimer)/(monomer)2 for the wild-
types and the mutants. To correctly quantify both the weak dimeric
bands and the strong monomeric bands, we exposed the ﬁlm for a
short period of time, quantiﬁed the monomeric bands, re-exposed the
ﬁlm for a longer time, and quantiﬁed the dimeric bands. Thus, the
band intensities were within the so-called linear range, proportional
to the protein concentrations. Detailed discussion of how to ensure
that the data are in the linear range is given in the Supplement to our
previous paper [42]. The effect of the mutations was quantiﬁed as
RNeu/V664E/RNeu=1.7 and RFGFR3/A391E/RFGFR3=1.5. Thus, the mutations
increase the cross-linking propensities of the two TM domains.3.3. Inhibition of Neu/V664E phosphorylation in stable B104-1-1 cells
B104-1-1 cells, which stably express Neu/V664E, were used to
investigate the effect of the TM domains on the activation of Neu/
V664E [47]. As shown in our previous work, the activation of RTKs is
dependent on their expression level [42]. Thus, phosphorylation
levels in the presence and in the absence of the TM domains can be
compared only when the expression levels of the receptors are
similar, necessitating the use of cells that stably express the receptor.
We ﬁrst veriﬁed that the expression level of Neu/V664E in the stable
line is not affected by the expression of the TM constructs. Fig. 5A
shows the effect of the expression of the TM domains on Neu/V664E
expression. These are the results from six independent experiments
for each TM domain. We used the Student t-test in Microsoft Excel to
compare the measurements to a null hypothesis of one (no effect of
the TM domains). The p-values were 0.33, 0.073, 0.23 and 0.87 for the
TM domains of FGFR3, FGFR3/A391E, Neu, and Neu/V664E, respec-
tively. These large p-values demonstrated that the transient expres-
sion of the TM domains in B104-1-1 stable cells did not have a
statistically signiﬁcant effect on the expression level of Neu/V664E.
Fig. 5B shows the phosphorylation of Neu/V664E in the presence of
the four TM domains, together with the standard errors. These are the
averages of six independent experiments. Again, we used the Student
t-test to compare the measurements to a null hypothesis of one (no
inhibition by the TM domains). The p-values obtained were 0.43,
0.083, 0.52 and 0.0006 for the TM domains of FGFR3, FGFR3/A391E,
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 Effect of TM domains on Neu/V664
phosphorylation in B104-1-1 cells
Fig. 5. Effect of the TM domains on the expression (A) and phosphorylation (B) of Neu/
V664E in stable cells. Results shown are averages of six sets of independent
experiments. Values in cells transfected with empty pcDNA 3.1 vectors are assigned
as one. The phosphorylation of Neu/V664E in stable cell lines can be speciﬁcally
inhibited by the TM domain of Neu/V664E.
257L. He et al. / Biochimica et Biophysica Acta 1808 (2011) 253–259used the Bonferroni correction formultiple comparisons, such that the
p-value cutoff for signiﬁcance was 0.013, not 0.05. Thus, only the Neu/
V664E TM domain exhibited a statistically signiﬁcant effect, reducing
the phosphorylation of Neu/V664E.
Next, we compared the effects of the four TM domains to each
other using ANOVA. We found a signiﬁcant p-value of 0.041,
demonstrating that the effects of the four TM domains are not the
same, with the Neu/V664E TM domain data set exhibiting the largest
difference. The ANOVA analysis further conﬁrmed the conclusion that
Neu/V664E speciﬁcally reduced the phosphorylation of Neu/V664E. In
contrast, the changes in the phosphorylation due to the presence of
FGFR3, FGFR3/A391E and Neu TM domains were not statistically
signiﬁcant. Importantly, our results showed that Neu/V664E could be
inhibited by Neu/V664E TM domain, but not by Neu TM domain. This
ﬁnding is indicative of speciﬁc inhibition, and suggests that hetero-
dimers of Neu and Neu/V664E form with lower probability than Neu/
V664E homodimers.These experiments, however, could not elucidate the effect of
FGFR3 and FGFR3/A391E TM domains on the phosphorylation of Neu/
V664E. These peptides were not trafﬁcked to the plasma membranes
of B104-11 cells efﬁciently, and thus the observed lack of inhibition
could be due to the low concentration of the FGFR3 TM domains in the
plasma membrane, rather than the lack of speciﬁc interactions
between them and Neu/V664E.
In Fig. 5, the average effect of Neu/V664E TM domain on Neu/
V664E phosphorylation was about 15% reduction (the largest
reduction observed in an experiment was about 20%). Thus, the effect
was modest. Yet, it may be important for biological function. For
instance, the A391Emutationwas found to increase the activation of a
chimeric Neu/FGFR3 receptor by no more than 40%, as compared to
wild-type (1) [42]. Yet, this mutation is pathogenic none the less.
Thus, an inhibitory effect of 15–20% may be non-trivial.
3.4. Inhibition of FGFR3/A391E phosphorylation in stable cells
A stable cell line expressing FGFR3/A391E was created using the
protocol described in Materials and methods. The four TM domains
were transiently expressed in these cells. Twenty-four hours after
transfection, the cells were starved for another 24 h, and then lysed
and analyzed using Western blotting. The expression and the
activation of FGFR3/A391E were probed with anti-N-FGFR3 (Santa
Cruz Technology) and anti-p-FGFR3 (Cell Signaling Technology)
antibodies, respectively. The expression of the TM domains was
probed with anti-VSV-G antibodies (Sigma-Aldrich). In Fig. 6A, we
show the effect of the four TM domains on FGFR3/A391E expression.
The statistical analysis for signiﬁcance revealed that none of the TM
domains affected the expression of FGFR3/A391E. In Fig. 6B, we show
the effect of the TM domains on FGFR3/A391E phosphorylation. The
statistical analysis, using the same approaches employed to analyze
the data in Fig. 4, demonstrated that none of the TM domains,
including the TM domain of FGFR3/A391E, decreased the phosphor-
ylation of FGFR3/A391E signiﬁcantly. This, however,may be due to the
fact that FGFR3 TMdomains are not trafﬁcked efﬁciently to the plasma
membrane of HEK 293 cells.
Importantly, Neu/V664E TM domain is efﬁciently trafﬁcked to the
cell membrane and does not reduce the phosphorylation of FGFR3/
A391E. Thus, Neu/V664E TM domain does not interact with the
unrelated FGFR3/A391E despite its ability to form hydrogen bonds
with the backbone of a neighboring helix. This ﬁnding further
conﬁrms that the inhibitory activity of Neu/V664E TM domain is
speciﬁc. Overall, the results that we presented here suggest that TM
domain peptides could be exploited in the future for the development
of speciﬁc inhibitors of mutant RTKs. However, the inhibitory effect
that we observed was rather modest, and thus the search for potent
inhibitors may require optimization of RTK TM domain sequences to
increase their dimerization propensities, without affecting the
speciﬁcity of their interactions.
4. Conclusion
In this study, we explored whether the phosphorylation of two
pathogenic RTK mutants, Neu/V664E and FGFR3/A391E, could be
reduced due to interactions of these receptors with their isolated TM
domains. The results pertaining to FGFR3/A391E TM domain were
inconclusive, since itwas not trafﬁcked efﬁciently to the cellmembrane.
However,we demonstrated thatNeu/V664ETMdomain can speciﬁcally
inhibit the phosphorylation of Neu/V664E, whereas the wild-type Neu
TM domain cannot. Furthermore, the TM domain of Neu/V664E did not
engage in promiscuous interactions with FGFR3/A391E. Overall, this
study suggests that the interactions between RTK TM domains are
speciﬁc despite the common structural motives, and thus could be












































































  Effect of TM domains on FGFR3/A391E
expression in stable cells
Effect of TM domains on FGFR3/A391E
phosphorylation in stable cells
Fig. 6. Effect of the TM domains on the expression (A) and phosphorylation (B) of FGFR3/
A391E in stable cells. Results shown here are averages of three sets of independent
experiments. Values in cells transfectedwith empty pcDNA3.1 vectors are assignedasone.
None of the TM domains could decrease the phosphorylation of FGFR3/A391E.
258 L. He et al. / Biochimica et Biophysica Acta 1808 (2011) 253–259However, the inhibitory effect is modest, and optimization of the RTK
TM sequences may be needed in order to develop better RTK inhibitors.
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